
## Fernando Torres

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6982622/publications.pdf Version: 2024-02-01



FERNANDO TOPPES

#	Article	IF	CITATIONS
1	Characteristics and outcomes among vaccinated lung transplant patients with breakthrough COVIDâ€19. Transplant Infectious Disease, 2022, 24, .	0.7	9
2	Diaphragmatic plication among lung transplant patients: A singleâ€center experience. Clinical Transplantation, 2022, , e14683.	0.8	1
3	Prognostic Value of Echocardiographic Variables Prior to and Following Initiation of Parenteral Prostacyclin Therapy. Chest, 2022, 162, 669-683.	0.4	5
4	Characteristics and outcomes among patients with communityâ€acquired respiratory virus infections during the first year after lung transplantation. Clinical Transplantation, 2021, 35, e14140.	0.8	3
5	Self-reactive antibodies associated with bronchiolitis obliterans syndrome subtype of chronic lung allograft dysfunction. Human Immunology, 2021, 82, 25-35.	1.2	3
6	Effects of Extracorporeal Membrane Oxygenation Initiation on Oxygenation and Pulmonary Opacities. The Journal of Critical Care Medicine, 2021, 7, 6-13.	0.3	2
7	Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis–associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 209-221.	2.5	88
8	Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction. Journal of Thoracic Disease, 2021, 13, 1466-1475.	0.6	2
9	Spectrum of findings on ventilation‒perfusion lung scintigraphy after lung transplantation and association with outcomes. Journal of Heart and Lung Transplantation, 2021, 40, 377-386.	0.3	2
10	Characteristics and outcomes among lung transplant patients with respiratory syncytial virus infection. Transplant Infectious Disease, 2021, 23, e13661.	0.7	3
11	Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA Vaccines. Vaccines, 2021, 9, 708.	2.1	51
12	Clinical characteristics, management practices, and outcomes among lung transplant patients with COVID-19. Journal of Heart and Lung Transplantation, 2021, 40, 936-947.	0.3	19
13	Postâ€infection pulmonary sequelae after COVIDâ€19 among patients with lung transplantation. Transplant Infectious Disease, 2021, 23, e13739.	0.7	14
14	Significance of Best Spirometry in the First Year After Bilateral Lung Transplantation: Association With 3-Year Outcomes. Transplantation, 2020, 104, 1712-1719.	0.5	9
15	P0229APPLICATION OF A RISK MITIGATION STRATEGY TO PREVENT EXCESS CARDIOVASCULAR RISK IN PULMONARY HYPERTENSION: LARIAT STUDY. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
16	Pre-existing self-reactive IgA antibodies associated with primary graft dysfunction after lung transplantation. Transplant Immunology, 2020, 59, 101271.	0.6	6
17	Characteristics and Outcomes of Lung Transplant Candidates With Preexisting Renal Dysfunction. Transplantation Proceedings, 2020, 52, 302-308.	0.3	9
18	Insult to Injury: Development of Alveolar Hemorrhage after Initiation of Extracorporeal Membrane Oxygenation. Indian Journal of Critical Care Medicine, 2020, 24, 1201-1205.	0.3	1

Fernando Torres

#	Article	IF	CITATIONS
19	Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial. European Respiratory Journal, 2019, 54, 1901030.	3.1	33
20	Long-term results of the DellVery for Pulmonary Arterial Hypertension trial. Pulmonary Circulation, 2019, 9, 204589401987861.	0.8	12
21	Incidence and variables associated with 30â€day mortality after lung transplantation. Clinical Transplantation, 2019, 33, e13468.	0.8	11
22	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respiratory Medicine,the, 2019, 7, 227-238.	5.2	122
23	Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension. Seminars in Arthritis and Rheumatism, 2019, 48, 1059-1067.	1.6	30
24	Diagnosis of pulmonary hypertension. European Respiratory Journal, 2019, 53, 1801904.	3.1	333
25	Mortality in Patients With Pulmonary Arterial Hypertension Treated With Continuous Prostanoids. Chest, 2018, 154, 532-540.	0.4	17
26	Interaction of pre-transplant recipient characteristics and renal function in lung transplant survival. Journal of Heart and Lung Transplantation, 2018, 37, 275-282.	0.3	7
27	FP804TWO-YEAR DURABILITY OF IMPROVEMENTS IN EGFR WITH BARDOXOLONE METHYL IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: THE LARIAT STUDY. Nephrology Dialysis Transplantation, 2018, 33, i634-i634.	0.4	0
28	Evaluation of current strategies for surveillance and management of donorâ€specific antibodies: Singleâ€center study. Clinical Transplantation, 2018, 32, e13285.	0.8	5
29	Association of pretransplant kidney function with outcomes after lung transplantation. Clinical Transplantation, 2017, 31, e12932.	0.8	13
30	Telomere length in patients with pulmonary fibrosis associated with chronic lung allograft dysfunction and post–lung transplantation survival. Journal of Heart and Lung Transplantation, 2017, 36, 845-853.	0.3	93
31	Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1). Respiratory Medicine, 2017, 126, 84-92.	1.3	15
32	Predictors of outcome among patients on extracorporeal membrane oxygenation as a bridge to lung transplantation. Clinical Transplantation, 2017, 31, e12990.	0.8	20
33	Characteristics and outcomes among patients with need for early dialysis after lung transplantation surgery. Clinical Transplantation, 2017, 31, e13106.	0.8	28
34	Severe pulmonary arterial hypertension: stratification of medical therapies, mechanical support, and lung transplantation. Heart Failure Reviews, 2016, 21, 347-356.	1.7	10
35	Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System. Chest, 2016, 150, 27-34.	0.4	48
36	Right atrial emptying fraction non-invasively predicts mortality in pulmonary hypertension. International Journal of Cardiovascular Imaging, 2016, 32, 1121-1130.	0.7	18

Fernando Torres

#	Article	IF	CITATIONS
37	Lung transplantation and gender effects on survival of recipients with cystic fibrosis. Journal of Heart and Lung Transplantation, 2016, 35, 1487-1496.	0.3	21
38	Longâ€Term Therapy with Oral Treprostinil in Pulmonary Arterial Hypertension Failed to Lead to Improvement in Important Physiologic Measures: Results from a Single Center. Pulmonary Circulation, 2015, 5, 513-520.	0.8	21
39	Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2015, 34, 1366-1375.	0.3	103
40	Exome sequencing links mutations in PARN and RTEL1 with familial pulmonary fibrosis and telomere shortening. Nature Genetics, 2015, 47, 512-517.	9.4	385
41	Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1102-1110.	2.5	138
42	Imatinib in Pulmonary Arterial Hypertension: Câ€Kit Inhibition. Pulmonary Circulation, 2014, 4, 452-455.	0.8	35
43	Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation. Lancet Respiratory Medicine,the, 2014, 2, 557-565.	5.2	225
44	Definitions and Diagnosis of Pulmonary Hypertension. Journal of the American College of Cardiology, 2013, 62, D42-D50.	1.2	1,467
45	Treprostinil for the treatment of pulmonary arterial hypertension. Expert Review of Cardiovascular Therapy, 2013, 11, 13-25.	0.6	25
46	Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients on Background Endothelin Receptor Antagonist and/or Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C) Tj ETQq0	) OorgBT /(	⊃v <b>ed</b> øck 10 T
47	International Classification of Diseases Coding Changes Lead to Profound Declines in Reported Idiopathic Pulmonary Arterial Hypertension Mortality and Hospitalizations. Chest, 2011, 139, 497-504.	0.4	61
48	Hemodynamics and Epoprostenol Use Are Associated With Thrombocytopenia in Pulmonary Arterial Hypertension. Chest, 2009, 135, 130-136.	0.4	49

49	Telomere Shortening in Familial and Sporadic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 729-737.	2.	5 481	
----	--	----	-------	--